Profile data is unavailable for this security.
About the company
Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
- Revenue in EUR (TTM)45.87bn
- Net income in EUR-198.00m
- Incorporated1952
- Employees88.50k
- LocationBayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
- Phone+49 214301
- Fax+49 2 143066328
- Websitehttps://www.bayer.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 3.13bn | 264.35m | 35.13bn | 2.50k | 140.03 | 52.74 | 112.88 | 11.23 | 2.25 | 2.25 | 27.82 | 5.96 | 0.8068 | 8.46 | 7.20 | 1,485,575.00 | 6.82 | -12.28 | 9.57 | -16.14 | 81.64 | 83.20 | 8.45 | -24.70 | 2.71 | 3.50 | 0.7737 | -- | 65.19 | 49.77 | 212.79 | -- | -3.56 | -- |
| Sun Pharmaceutical Industries Ltd | 5.29bn | 976.34m | 37.90bn | 43.00k | 38.85 | -- | 30.38 | 7.17 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Haleon PLC | -115.01bn | -115.01bn | 41.92bn | 24.00k | -- | 2.31 | -- | -- | -- | -- | -- | 1.77 | -- | -- | -- | -- | -- | 3.67 | -- | 4.23 | -- | 62.28 | -- | 11.97 | 0.6327 | -- | 0.3464 | 218.58 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| CSL Ltd | 13.08bn | 2.52bn | 43.38bn | 32.07k | 17.22 | 2.66 | 12.42 | 3.32 | 8.71 | 8.71 | 45.14 | 56.34 | 0.4019 | 1.20 | 5.16 | 684,542.30 | 8.10 | 8.58 | 9.87 | 10.61 | 51.93 | 52.91 | 20.16 | 19.71 | 1.12 | 10.01 | 0.3494 | 47.42 | 5.12 | 11.20 | 13.63 | 7.38 | -6.11 | 7.95 |
| Zoetis Inc | 7.98bn | 2.25bn | 45.05bn | 14.50k | 21.03 | -- | 16.90 | 5.65 | 6.02 | 6.02 | 21.33 | -- | -- | -- | -- | 652,896.60 | -- | 16.21 | -- | 19.61 | 71.87 | 70.68 | 28.23 | 27.03 | -- | 20.95 | -- | 30.59 | 2.28 | 7.24 | 7.52 | 10.29 | 6.51 | 20.11 |
| Bayer AG | 45.87bn | -198.00m | 45.18bn | 88.50k | -- | 1.53 | 13.28 | 0.985 | -0.2015 | -0.2015 | 46.69 | 30.11 | 0.4344 | 1.58 | 4.52 | 494,165.80 | -0.1639 | -2.66 | -0.2205 | -3.61 | 56.35 | 57.98 | -0.3772 | -6.88 | 0.7096 | 2.33 | 0.5717 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.78bn | 910.80m | 45.30bn | 20.24k | 49.69 | 6.50 | -- | 11.99 | 1.17 | 1.17 | 4.84 | 8.97 | 0.5312 | 1.71 | 5.75 | 1,530,951.00 | 12.82 | 12.67 | 14.40 | 14.00 | 85.49 | 85.64 | 24.14 | 20.06 | 6.20 | -- | 0.0014 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Takeda Pharmaceutical Co Ltd | 24.63bn | 623.08m | 49.28bn | 47.46k | 77.69 | 1.16 | 10.38 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| UCB SA | 6.85bn | 1.33bn | 54.36bn | 9.38k | 40.74 | 5.48 | 28.43 | 7.94 | 6.86 | 6.86 | 35.27 | 50.96 | 0.4174 | 1.46 | 4.26 | 730,219.70 | 8.12 | 4.98 | 10.21 | 6.20 | 73.38 | 71.71 | 19.45 | 13.00 | 1.01 | 11.23 | 0.2291 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Merck KGaA | 21.27bn | 2.96bn | 55.56bn | 62.35k | 18.81 | 1.92 | 11.41 | 2.61 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
Data as of Feb 13 2026. Currency figures normalised to Bayer AG's reporting currency: Euro EUR
23.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 36.85m | 3.75% |
| Amundi Asset Management SASU (Investment Management)as of 05 Feb 2026 | 31.33m | 3.19% |
| Silchester International Investors LLPas of 29 Aug 2025 | 29.41m | 2.99% |
| Harris Associates LPas of 29 Apr 2025 | 29.29m | 2.98% |
| Dodge & Coxas of 13 Feb 2025 | 28.23m | 2.87% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 21.85m | 2.22% |
| Geode Capital Management LLCas of 12 Feb 2026 | 13.93m | 1.42% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 12.79m | 1.30% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 12.35m | 1.26% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 10.97m | 1.12% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
